• Mashup Score: 0
    NSCLC, long-term survival with neoadjuvant immunotherapy - 1 year(s) ago

    Event-free survival at 3 years is not influenced by surgical parameters in resectable NSCLC

    Source: Daily Reporter
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of DrJNaidoo
      DrJNaidoo

      #ELCC23 Day 2 Highlight: 3-yr update Ph III CM816 trial neoadjuvant chemo-IO in NSCLC: - 57%pts event-free at 3yrs v 47% with chemo - less CNS progression w chemo-IO - 4-gene inflam signature may associate with pCR @myESMO @IASLC @nicogirardcurie #LCSM https://t.co/J1tPZethqW https://t.co/O0Q2jy5sPK

  • Mashup Score: 4
    How can lung cancer prevention be improved? - 1 year(s) ago

    The key is cooperation between multiple organisations patient groups, pharmaceutical companies and regulatory agencies

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ELCC23:How can #LungCancer prevention & treatment strategies be improved in resource-restricted settings? The key to overcoming barriers to effective prevention & treatment involves cooperation between multiple medical organisations 👉https://t.co/YINvtEf3oH @clarissamathias https://t.co/gfqGmzUPjw

  • Mashup Score: 3
    Durable efficacy of amivantamab in  mutated NSCLC - 1 year(s) ago

    Updated results from the CHRYSALIS trial in pretreated NSCLC with EGFR Exon 20 insertion mutations

    Source: Daily Reporter
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrJNaidoo
      DrJNaidoo

      #ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM https://t.co/8bsGk75lvp https://t.co/xztiQ3V6FB

  • Mashup Score: 3
    Mesothelioma treatment: from hopeless to hopeful - 1 year(s) ago

    Recipient of the Heine H. Hansen Award 2023, Prof. Paul Baas charts the course of mesothelioma treatment over the last 30 years

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ELCC23:Mesothelioma treatment: From hopeless to hopeful Recipient of the Heine H. Hansen Award 2023, Paul Baas charts the course of mesothelioma treatment over the last 30 years and warns that progress has been made only in some areas of the world. 👉https://t.co/iXXoy6JNX0 https://t.co/in0sQyuk8o

  • Mashup Score: 2
    Durable efficacy of amivantamab in  mutated NSCLC - 1 year(s) ago

    Updated results from the CHRYSALIS trial in pretreated NSCLC with EGFR Exon 20 insertion mutations

    Source: Daily Reporter
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of APassaroMD
      APassaroMD

      #ELCC23, IMO *THE slide* of the 1st day by @Piuchagarrido #LCSM Long-term analysis of #Amivantamab in pts with EGFR Ex20ins, confirming that 13% of pts remained on treatment for a median duration of 2.6 years ◾️mPFS: 6.9 months (95% CI, 5.6–8.8) ◾️mOS: https://t.co/tMZRJlSYmh… https://t.co/IsUvFsJX7x https://t.co/XozYMjPiUQ

Load More